Prevention Of Stroke In Nonvalvular Atrial Fibrillation
Key Points
Key Points
- The absolute risk of stroke varies 20-fold among AF patients according to age and associated vascular comorbidities. Current AHA2 guidelines use the CHADS stratification scheme.
- The major risk of antithrombotic medications used to lower the incidence of AF-related stroke is bleeding.
- For warfarin, this involves balancing a bleeding risk of 1% to 12% per year.
- The advent of several new antithrombotic agents offers alternatives to warfarin and may lower the thromboembolic risk threshold for initiating therapy in patients with AF.
Diagnosis
...iagnosi...
Table 1. Stroke Risk in Patients With Nonvalvu...
...e 1. Patterns of Atrial Fibrill...
Treatment
...eatment...
...arfarin (A)300167
...igatran (B)300167
...ixaban (B)30...
...aban (B)300167...
...efficacy of combining dabigatran, rivaroxaba...
... Clopidogrel & Warfarin...
Adjusted-dose warfarin (target INR – 2.0-3...
Antiplatelet therapy with aspirin is recommended f...
...patients with AF deemed unsuitable for...
...or patients with ischemic stroke or TIA with parox...
For patients unable to take oral anticoagulants,...
...of clopidogrel plus aspirin carries a risk of ble...
...abigatr...
...tran is useful as an alternative to w...
Dabigatran 150 mg twice daily is a...
...pharmacokinetic data, the use of dabigatran 75 mg...
...are no data to support the use of dabigatra...
...pixaban
...ixaban 5 mg twice daily is an efficacious alt...
...its safety and efficacy have not been established,...
...ice daily is a relatively safe and...
...though its safety and efficacy have not been...
...ixaban should NOT be used if the...
...aroxaban...
...nonvalvular AF who are at moderat...
...renal impairment and nonvalvular AF who are at...
...an should NOT be used if the CrCI i...
...Agents Recommended for Stroke PreventionaHavi...
...re 2. Prevention of Stroke in Nonvalvular Atrial...